ReviewNature medicine2017
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
Review in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 299 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
299 citing papers in PubMed, 5 syntheses or guidelines pooled it, 578 citations in OpenAlex.
- Cannabis-Derived Compounds Against Plasmodium sp.: A Systematic Review of Preclinical Studies.Tropical medicine & international health : TM & IH · 2026Pooled it
- Malaria and Helminthic Co-Infection during Pregnancy in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- A Dual, Systematic Approach to Malaria Diagnostic Biomarker Discovery.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: A systematic review of clinical studies from two malaria endemic regions - India and sub-Saharan Africa.International journal for parasitology. Drugs and drug resistance · 2021Pooled it
- Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews · 2021Pooled it
- Parasite clearance of two commonly administered artemisinin-based combination therapies in under-five children with uncomplicated malaria in a comprehensive healthcare facility in South-Western Nigeria: a randomised controlled trial.BMC infectious diseases · 2025Trial
- Trial
- Identification of PfSR1-MT as melatonin-responsive GPCR-like candidate from the human malaria parasiteCurrent research in microbial sciences · 2026Article
- Article
- Revisiting Glutathione Transferases ofPharmaceuticals (Basel, Switzerland) · 2026Review
- Compound effector genes suppress malaria parasite infections in gene-drive population modification strains of the African malaria mosquitoes, Anopheles gambiae and Anopheles coluzzii.G3 (Bethesda, Md.) · 2026Article
- Repurposing 6‑Anilinopurine Derivatives That Exhibit PfHDAC1 Inhibition and Antimalarial Activity against Asexual and Sexual Stages ofACS omega · 2026Article
- Selective targeting ofAntimicrobial agents and chemotherapy · 2026Article
- Elucidating the Structure and Identity of Pinckneyin, a Historical Natural Product fromACS omega · 2026Article
- Spatial and temporal description of antimalarial drug resistance markers in Ghana using targeted amplicon deep sequencing.Antimicrobial agents and chemotherapy · 2026Article
- Glutathione redox system as a therapeutic target for Plasmodium: Opportunities, Challenges, and future perspectives.Folia microbiologica · 2026Review
- Rising of antimalarial drug resistance Pfmdr1 N86Y and Pfcrt K76T gene in Ethiopia: a systematic review and meta-analysis.Journal, genetic engineering & biotechnology · 2026Article
- Structural and mechanistic insights into the inhibition of Plasmodium falciparum MDR1.Nature communications · 2026Article
- National genomic profiling of Plasmodium falciparum antimalarial resistance in Zambian children participating in the 2018 malaria indicator survey.Scientific reports · 2026Article
- A heterologous marker-free selection approach for CRISPR/Cas9-based gene editing in the malaria parasitemSphere · 2026Article
239 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.